Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Vision Nets $6.3M in Series B Backing

NEW YORK (GenomeWeb News) – The Parisian genomic testing company Genomic Vision said today that it has raised €4 million ($6.3 million) in a round of Series B financing from one new and one previous investor.
 
The new backer, Vesalius BioCapital, joined Society Generale Asset Management Alternative Investments in providing the funding.
 
Genomic Vision uses a technology called Molecular Combing for direct visualization of single molecules to detect qualitative and quantitative changes in the genomic landscape. The company exclusively licensed the technology from the Pasteur Institute.
 
The company said it plans to use the funds to expand its in-house R&D programs and automation, and to strengthen its ongoing collaborative programs with partners.
 
“This support from our investors will help us to develop our products and services more quickly and enable us to take advantage of growing market opportunities," Genomic Vision President, CEO, and Founder Aaron Bensimon said in a statement.
 
"We believe very strongly that [Genomic Vision’s] genomic tests will be useful for cancers, genetic diseases, viral diseases and many other applications with wide potential markets,” SGAM AI Bioconvergence Team Managing Partner Jean-Yves Nothias said in a statement.
 
The company said it is focused on three areas: biomarker-based diagnostics for identifying and managing disease; testing drug compounds by studying DNA replication in cancer cells; and developing drug response biomarkers.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.